Evaluation of the time dependent variability of the anti-factor Xa activity of therapeutic nadroparin in critically ill patients: a pharmacokinetic study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON20466

Enrollment

Registered

2019-11-26

Start date

2020-07-23

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Critically ill patients

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: (1) Admitted to the Intensive Care with nadroparin in therapeutic dose (1-daily or 2-daily) (2) Age = 18 years

Exclusion criteria

Exclusion criteria: (1) Pregnancy (2) Requiring hemodialysis (HD) or Continuous Veno-Venous Hemofiltration (CVVH) (3) Treated with a DOAC, unfractionated heparin, another LMWH, or a GP IIb / IIIa receptor antagonist 72hours to 0 hours before the first bloodsample is drawn or during bloodsampling. (4) Participation in another study

Design outcomes

Primary

Measure	Time frame
The incidence of inadequate estimated peak anti-factor-Xa levels after therapeutic nadroparin in a general intensive care unit population	—

Secondary

Measure	Time frame
To evaluate the pharmacokinetics of therapeutic nadroparin in a general intensive care unit population by measuring anti-factor Xa levels.	—

Contacts

Public ContactJelmer (J.G.) Sytema

Martini Ziekenhuis

j.sytema@mzh.nl050-5246783

Outcome results